ReviewDrugs2019
Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Unraveling Type 1 Diabetes: Integrating Microbiome, Metabolomics, and Immunomodulation for Next-Generation Therapies.International journal of molecular sciences · 2025Review
- Review
- Unmet needs in the treatment of type 1 diabetes: why is it so difficult to achieve an improvement in metabolic control?Nutrition & diabetes · 2024Review
- A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023 · on this mapReview
- A Deep Learning Framework for Automatic Meal Detection and Estimation in Artificial Pancreas Systems.Sensors (Basel, Switzerland) · 2022Article
- Fault Tolerant Strategies for Automated Insulin Delivery Considering the Human Component: Current and Future Perspectives.Journal of diabetes science and technology · 2021Review
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.International journal of molecular sciences · 2021Review
- Decreased serum fibroblast growth factor 19 level is a risk factor for type 1 diabetes.Annals of translational medicine · 2021Article
- Study of blood glucose and insulin infusion rate in real-time in diabetic rats using an artificial pancreas system.PloS one · 2021Article
- Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors.Sensors (Basel, Switzerland) · 2020Review
- Closed-loop bioelectronic medicine for diabetes management.Bioelectronic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes is characterised by insulin deficiency caused by autoimmune destruction of the pancreatic beta cells. The treatment of type 1 diabetes is exogenous insulin in the form of multiple daily injections or continuous subcutaneous insulin infusion. Advances in diabetes technology have been exponential in the past few decades, culminating in studies to develop an automated artificial pancreas, also known as the closed-loop system. This has recently led to a commercially available, hybrid artificial pancreas in the USA and Europe. This review article aims to provide an overview of the rationale for an artificial pancreas system and an update of the current state of artificial pancreas development. We explore the different types of artificial pancreas systems being studied, including the use of adjunctive therapy, and the use of these systems in different groups of users. In addition, we discuss the potential psychosocial impact and the challenges and limitations of implementing artificial pancreas use into clinical practice.
Indexed as
Identifiers
31190305What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.